New antiarrthythmics in atrial fibrillation
Main Article Content
Keywords
Atrial fibrillation, Cardiac arrhythmia, Anticougulants, Anti-arrhythmia agent
Abstract
Atrial fibrillation is the most common cardiac arrhythmia responsible for a significant morbidity and mortality. In recent years, progress has been made in determining the genetic abnormalities, the use of anticoagulants as a component of a primary treatment strategy in many patients who have a high risk of recurrence and for thromboembolism, and newer and safer antiarrthythmics are now available. The aim of this paper is to discuss about this topic and antiarrhythmic therapy.
References
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18): 2370-2375.
Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158(3):229-234.
Iturralde-Torres P, Lara-Vaca S, Cordero-Cabra A, Nava-Townsend S, Mendoza C, Márquez MF, et al. Diseño de un registro multicéntrico para evaluar control del ritmo contra control de la frecuencia en fibrilación auricular: Registro Mexicano de Fibrilación Auricular (ReMefa). Arch Cardiol Mex 2011;81(1):13-17.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354.
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98(10):946-952.
Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109(12):1509-1513.
Duray GZ, Ehrlich JR, Hohnloser SH. Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Curr Opin Cardiol 2010;25:53-58.
Camn AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guías de práctica clínica para el manejo de la fibrilación auricular. Segunda edición corregida. Rev Esp Cardiol 2010;63(12):1483.e1-e83.